Inhaled Acetylcysteine Recommendations

FDA-Approved Indications and Evidence-Based Use

The American College of Chest Physicians notes that inhaled acetylcysteine is inactive against cough in patients with chronic bronchitis, and cough frequency and intensity may be independent of mucus properties in chronic bronchitis 1
The British Thoracic Society recommends considering a trial of mucoactive treatment in patients with bronchiectasis who have difficulty in sputum expectoration, and performing an airway reactivity challenge test when inhaled mucoactive treatment is first administered 2
The Cystic Fibrosis Foundation concludes that evidence is insufficient to recommend for or against routine chronic use of inhaled N-acetylcysteine to improve lung function or reduce exacerbations, with a level of evidence that is poor, net benefit that is zero, and a grade of recommendation that is "I" (insufficient evidence) 3
The European Respiratory Society guidelines note that inhaled N-acetylcysteine may cause bronchoconstriction, particularly in patients with reactive airways 4
Oral mucolytics, such as N-acetylcysteine 600mg twice daily, may be considered for patients with moderate-severe COPD and recurrent exacerbations despite optimal inhaled therapy 5
The use of inhaled acetylcysteine is not recommended for sinonasal congestion or phlegm, as there is no evidence to support this indication 6

For bronchiectasis, hypertonic or normal saline for humidification to facilitate airway clearance is recommended (Grade D recommendation) 2
For chronic bronchitis/COPD, ipratropium bromide to improve cough (Grade A recommendation) and short-acting β-agonists for bronchospasm and dyspnea (Grade A recommendation) are preferred alternatives 1
For cystic fibrosis, dornase alfa is the only mucolytic with proven efficacy 3

The Cystic Fibrosis Foundation concludes that evidence is insufficient to recommend for or against routine chronic use of N-acetylcysteine for chronic bronchitis/COPD with productive cough, with poor quality evidence, zero net benefit, and an "I" grade (insufficient evidence) recommendation 7
Oral NAC 600 mg twice daily may reduce exacerbations in patients with moderate-to-severe COPD who continue to have recurrent exacerbations despite optimal inhaled therapy, according to the American Thoracic Society 8
For acute bronchitis, acetylcysteine provides no benefit, and supportive care is appropriate, as recommended by the American College of Emergency Physicians 9, 10

The American College of Chest Physicians suggests that oral NAC 600 mg twice daily may be used to reduce exacerbations in patients with moderate-to-severe COPD, but this is not for cough treatment 8